Author for correspondence:
Michael Otto
e-mail: motto@niaid.nih.gov

Bacterial strategies of resistance to antimicrobial peptides

Hwang-Soo Joo, Chih-Iung Fu and Michael Otto

Pathogen Molecular Genetics Section, Laboratory of Bacteriology, National Institute of Allergy and Infectious Diseases (NIAID), US National Institutes of Health (NIH), 50 South Drive, Bethesda, MD 20892, USA

iD MO, 0000-0002-2222-4115

Antimicrobial peptides (AMPs) are a key component of the host's innate immune system, targeting invasive and colonizing bacteria. For successful survival and colonization of the host, bacteria have a series of mechanisms to interfere with AMP activity, and AMP resistance is intimately connected with the virulence potential of bacterial pathogens. In particular, because AMPs are considered as potential novel antimicrobial drugs, it is vital to understand bacterial AMP resistance mechanisms. This review gives a comparative overview of Gram-positive and Gram-negative bacterial strategies of resistance to various AMPs, such as repulsion or sequestration by bacterial surface structures, alteration of membrane charge or fluidity, degradation and removal by efflux pumps.

This article is part of the themed issue 'Evolutionary ecology of arthropod antimicrobial peptides'.

1. Introduction

Antimicrobial peptides (AMPs) represent an important part of innate immune defences in many organisms [1]. They contribute to immune defences on epithelial surfaces and form part of the variety of antimicrobial agents by which leucocytes kill microorganisms after ingestion [2]. Many AMPs have activity against a wide range of pathogens. In addition to their antimicrobial activity, AMPs also have a signalling function. For example, they can activate components of the human acquired immune system, such as T cells and dendritic cells [3].

AMPs are synthesized as proforms before processing to the active, mature peptides occurs. Most AMPs are cationic (cationic AMPs, CAMPs) and show pronounced amphipathy. Although for many AMPs the mode of action is incompletely understood, these features contribute to binding to the anionic bacterial surface and integration into the cytoplasmic membrane, where many AMPs form pores to kill the target microorganism [4].

Most AMPs in humans belong to the beta-defensin family. Human beta-defensins 1–4 are produced by keratinocytes on the skin [5]. The only member of the cathelicidin family produced in humans is the LL-37 peptide [6]. While these peptides are cationic, humans also produce an anionic AMP, dermcidin, which recently has been shown to also work by pore formation in target membranes [7,8].

AMPs have often been suggested as potential novel antimicrobial compounds [9]. Notably, their commonly bactericidal mode of action makes them potential candidates for difficult-to-treat infections by slow-growing bacteria, such as biofilm infections. As the development of resistance to antimicrobial compounds represents one of the most serious problems for healthcare systems, a detailed understanding of resistance mechanism to AMPs is of vital importance.

AMP resistance mechanisms include proteolytic degradation or sequestration by secreted proteins, impedance by exopolymers and biofilm matrix molecules, circumvention of attraction by cell surface/membrane alteration, and export by efflux pumps. This review gives an overview of each mechanism in Gram-positive and Gram-negative bacteria and finishes by a presentation of mechanisms bacteria

THE ROYAL SOCIETY PUBLISHING

Figure 1. Schematic diagram of bacterial AMP resistance mechanisms. Mechanisms in Gram-positive bacteria are shown on the left, and in Gram-negative bacteria on the right. Gram-positive bacteria retain the Gram stain owing to their thick peptidoglycan cell wall, while Gram-negative bacteria only have a thin peptidoglycan (PG) layer but possess an additional so-called 'outer membrane'. 1, Proteolytic degradation by extracellular proteases; 2, sequestration by extracellular proteins or extracellular matrix; 3, electrostatic repulsion by alanylated teichoic acids (TA); 4, electrostatic repulsion by aminoacylated PG; 5, evasion of lipid II-binding AMPs by pentapeptide alteration; 6, export of AMPs by efflux pumps; 7, proteolytic cleavage by outer membrane protease or cytosolic protease after uptake by transporters; 8, sequestration or steric hindrance by O-antigen of lipopolysaccharide (LPS); 9, electrostatic repulsion by amine compound-added lipid A; 10, enhanced rigidity by lipid A acylation.

Table 1. Overview of bacterial resistance mechanisms against antimicrobial peptides.

mechanisms	Gram-positive bacteria	Gram-negative bacteria
extracellular proteins	proteolytic degradation	proteolytic degradation
	sequestration	
exopolymers	PIA, PGA	alginate, polysialic acid
surface modification	repulsion by D-alanylation of TA	repulsion by lipid A phosphate modification
	steric hindrance by L-rhamnosylation of WTA	increased OM rigidity by lipid A acylation
	lipid II modification	O-antigen of LPS
cytoplasmic membrane alteration	charge repulsion by PG amino-acylation	increased IM rigidity by PG acylation
efflux pumps	export by ABC transporters	export by RND family efflux pumps

have to sense the presence of AMPs (see table 1 and figure 1 for a summary list and graphical presentation, respectively).

2. Extracellular proteins

Secreted bacterial proteins, such as proteases, are the first bacterial defence mechanisms that AMPs encounter when interacting with bacteria. Proteolytic degradation of AMPs by extracellular enzymes represents a simple, yet effective way

of providing AMP resistance to microorganisms. Commensal bacteria that live on mammalian epithelial surfaces, such as staphylococci, secrete various proteases. In staphylococci, these include metalloproteases such as aureolysin and SepA, and serine endopeptidases such as the V8 protease, which are known to degrade linear CAMPs such as the human cathelicidin LL-37 [10,11]. Group A *Streptococcus* produces a protease called SpeB. This cysteine protease has been shown to fragmentize many host AMPs, including LL-37 and beta-defensins [12–15]. Interestingly, exploiting host proteins can intensify

the proteolytic activity of SpeB. Namely, interaction of SpeB with cell wall-anchored G-related alpha2M-binding (GRAB) protein leads to a surface-bound complex of SpeB and a host proteinase inhibitor, alpha2-macroglobulin, which shows increased activity towards LL-37 [16,17]. In addition, as a secondary effect of SpeB proteolytic activity, degraded host proteoglycans release dermatan sulfate, which completely neutralizes human alpha-defensin, HNP-1 [18]. Finally, proteases from another Gram-positive pathogen, *Enterococcus faecalis*, and the Gram-negative *Pseudomonas aeruginosa* and *Proteus mirabilis* have also been reported to degrade LL-37 [12].

One of the most intensively studied group of proteases in Gram-negative bacteria is the omptin family, a group of aspartate proteases found in the enterobacterial outer membrane (OM) [19,20]. Some representative members of that protease, such as OmpT in *Escherichia coli*, PgtE in *Salmonella enterica* serotype Typhimurium (*S. typhimurium*) and Pla in *Yersinia pestis*, have been demonstrated to cleave AMPs including LL-37, the homologous murine cathelicidin-related antimicrobial peptide (CRAMP) and protamine [21–23]. Along with the opmtin family of proteases, metalloproteases play an important role in the defence of Gram-negative bacteria towards AMPs. For example, the metalloprotease ZapA of *P. mirabilis* neutralizes multiple targets such as LL-37, human beta-defensin HBD-1, and the porcine AMP protegrin-1 [24]. *Burkholderia cenocepacia* produces two metalloproteases, ZmpA and ZmpB, which can degrade various CAMPs [25]. Interestingly, ZmpA cleaves linear LL-37, whereas ZmpB targets the nonlinear HBD-1 [25]. Some Gram-negative bacteria also degrade AMPs in the intracellular environment after import by specific transport proteins. *S. typhimurium* and *Haemophilus influenzae* produce an ABC transporter encoded by the *sapABCDFZ* operon, which was reported to increase bacterial resistance to CAMPs [26–28]. Binding of CAMPs by SapA leads to increased expression of the genes in the *sap* operon, whose four-component ABC transporter product transfers CAMPs into the cytosol for intracellular proteolytic degradation [28–30]. *H. influenzae* SapA has been shown to bind to diverse AMPs such as LL-37, HNP-1, HBD-2, HBD-3 and melittin [31].

Finally, it needs to be stressed that the inactivation of AMPs by proteases is highly dependent on the structure of the target peptide [1]. For example, a linear AMP such as LL-37 is more prone to degradation than AMPs with nonlinear structures that contain disulfide bonds. The introduction of disulfide bonds, or the even more sophisticated post-translational modification found in some bacterial AMPs (bacteriocins) such as lantibiotics represent resistance mechanisms of AMPs towards proteolytic degradation by the host or competing microorganisms, exemplifying the multi-faceted evolutionary interplay of AMP producers and resistant microorganisms [1,32].

Along with proteolysis, sequestration has an important role in extracellular protein-mediated resistance to AMPs. Staphylokinase is one of the most prominent extracellular AMP-sequestering molecules. It is encoded by the *sak* gene in *Staphylococcus aureus* and sequesters alpha-defensins (HNP-1 and 2) [33,34]. Furthermore, binding to LL-37 increases staphylokinase-dependent plasminogen activation, which represents another crucial role of staphylokinase in pathogenesis [35]. Intriguingly, the activation of plasminogen by streptokinase (Ska) of group A streptococci, in addition to the original activities of plasmin such as fibrin clot degradation [36], leads to the destruction of LL-37 [37]. Another well-known streptococcal sequester, streptococcal inhibitor of complement (SIC), protects *Streptococcus pyogenes* from defensins and LL-37 [38] as well as the membrane attack complex [39]. Finally, some streptococcal cell surface-attached proteins such as the M1 protein of *S. pyogenes* and the PilB pilin subunit of *Streptococcus agalactiae* can bind cathelicidins (LL-37 and CRAMP), contributing to streptococcal AMP resistance [40,41].

3. Biofilms and exopolymers

Bacterial biofilm is a consortium of surface-attached bacterial cells that are embedded in a matrix composed mainly of extracellular proteins, extracellular DNA and exopolysaccharides (EPS) [42,43]. Bacteria in biofilms exhibit higher resistance (up to 1000-fold) to antibiotics and AMPs than planktonic bacteria [44,45]. The increased resistance is thought to be partly owing to the decreased penetration of AMPs through the matrix [46]. EPS and capsular polysaccharides (CPS) impede AMPs by capturing or repelling them. Polysaccharide intercellular adhesin (PIA, also known as poly-*N*-acetyl glucosamine), which is produced by *S. aureus*, *Staphylococcus epidermidis*, and a variety of other bacteria including other staphylococci and *E. coli*, is responsible for the resistance to cationic HBD-3 and LL-37 as well as anionic dermcidin [47,48]. IcaB-mediated deacetylation of PIA increases the positive net charge in PIA. This results in increased repulsion to CAMPs, but perhaps also increased sequestration of dermcidin, in addition to forming a mechanical barrier for both types of AMPs [49]. Additionally, PIA is crucial for *in vitro* and *in vivo* biofilm formation, thus contributing to biofilm formation as a general AMP resistance mechanism [49–51]. On the other hand, impedance of CAMPs such as polymyxin B, HNP-1, HBD-1, lactoferrin and protamine by the anionic CPS of *Klebsiella pneumoniae*, *Streptococcus pneumoniae* or *P. aeruginosa* is presumably the result of structural hindrance as well as electrostatic trapping [52,53]. Capsules in other streptococci also have an important role in sequestering AMPs. Hyaluronic acid capsule as well as M protein of group A streptococci mediate resistance to LL-37 [54]. Capsule synthesized by a phosphoglucomutase homologue in *Streptococcus iniae* has a role in resistance to the fish AMP, moronecidin [55]. Furthermore, as briefly mentioned in §2, *P. aeruginosa*, *E. faecalis* and *S. pyogenes* can exploit host polysaccharide to sequester AMPs after the degradation of the host proteoglycan matrix by secreted bacterial proteases [18].

In *Pseudomonas* species, alginate is a major component of the biofilm matrix. It is an acylated polysaccharide comprising anionic sugars such as guluronic acid and mannuronic acid [56,57], whose role in AMP resistance in biofilms was shown by genetic overexpression [58]. Mechanisms of resistance to LL-37 in *P. aeruginosa* and other lung pathogens are largely dependent on sequestration by EPS [59,60]. Finally, the Gram-negative bacterium, *Neisseria meningitidis*, has a capsular polysialic acid that prevents surface binding of defensins, cathelicidins, protegrins and polymyxin B [61,62].

Poly-gamma-glutamic acid (PGA), which is a homopolymer of glutamic acid linked by gamma-amide bonds, forms an extracellular capsule protecting bacteria from phagocytosis [63]. PGA is found only in Gram-positive bacteria, mainly in *Bacillus* species and coagulase-negative staphylococci including *S. epidermidis* [64,65]. In addition to its role in resisting ingestion by leucocytes, PGA provides protection from LL-37, HBD-3 and dermcidin, similar to PIA. However,

in contrast to PIA, PGA does not directly facilitate biofilm formation [64,66], although the PGA biosynthesis *cap* operon is upregulated in biofilms of *S. epidermidis* [67,68].

Finally, it is important to note that AMPs have gained much attention as alternatives to traditional antibiotics in the treatment of biofilm-associated infection. This is mainly because the mode of action of AMPs is usually bactericidal, whereas many traditional antibiotics are commonly bacteriostatic and target fast-growing bacteria, thus lacking efficiency against biofilms [68,69]. However, despite numerous efforts of biofilm control with natural or synthetic AMPs, biofilm-intrinsic AMP resistance complicates the use of AMPs for the treatment of biofilm infections [70,71].

4. Surface modification

The bacterial cell envelope represents a major impediment for AMP activity. Because Gram-positive and Gram-negative bacteria have distinct cell envelope structures, they apply different strategies to modify their cell surface to resist AMPs. The key molecules for this purpose are anionic polymers attached to the outermost cell surface, teichoic acids (TA) in the Gram-positive cell wall and lipopolysaccharide (LPS) in the Gram-negative OM.

TA is the most abundant component in the Gram-positive cell wall, representing over 60% of its total mass [72]. It is composed of disaccharide anchors and phosphodiester-linked polyglycerol phosphate or polyribitol phosphate, which is responsible for the negative net charge of TA [73,74]. According to the anchoring location of TA to the cell surface, one distinguishes wall teichoic acid (WTA) and lipoteichoic acid. D-Alanylation on free hydroxyls of the repeating sugars, driven by the gene products of the *dltABCD* locus, adds a positive charge to TA. This generally lowers attraction of CAMPs and was shown in *S. aureus* for HNP-1,2,3, protegrins, magainin II, gallidermin and nisin [75]. In a more recent study on group B *Streptococcus*, it was shown that D-alanylation also increases cell wall density, which suggests a dual role of DltABCD, leading to electrostatic repulsion and a reduction of surface permeability [76]. D-Alanylation of TA as an AMP resistance strategy is widely used by various Gram-positive bacteria, including *Staphylococcus*, *Streptococcus* and *Bacillus* [75–83]. Interestingly, the Gram-negative bacterium, *Bordetella pertussis*, has a Dlt homologue, Dra, which leads to D-alanylation on the OM, resulting in a decreased negative charge that increases resistance to AMPs such as LL-37, HNP-1, HNP-2 and polymyxin B [84]. Although the target component in the OM is yet to be determined, this finding suggests that Dlt-homologous proteins may have an even more widespread role in AMP resistance than previously believed. Recently, it was reported that L-rhamnosylation of WTA in *L. monocytogenes* protects from AMPs such as cathelicidins and gallidermin by increasing steric hindrance in the cell wall, proposing yet another TA decoration-related resistance mechanism [85].

Owing to its pivotal role in cell proliferation, the bacterial peptidoglycan precursor, lipid II, represents a further prominent AMP target. Lipid II is a cell wall building block consisting of undecaprenyl pyrophosphate and pentapeptide connected to the cell wall disaccharide of *N*-acetyl muramic acid (MurNAc) and *N*-acetyl glucosamine (GlcNAc) [86]. Many bacteria modify lipid II to evade AMP killing. Of note, unlike AMP-induced envelope alteration, modification of lipid II is a consistent change. The best-known lipid II modification is replacement of the terminal D-alanine to evade the activity of the glycopeptide antibiotic, vancomycin. Vancomycin binds to the D-Ala–D-Ala dipeptide found in the cell wall-cross-linking pentapeptide bridge and blocks the transpeptidation reaction that is required for cell wall synthesis [87]. Vancomycin-resistant strains contain lipid II with D-lactate or D-serine instead of the terminal D-alanine and show 1000-fold increased resistance [88]. Another well-known group of AMPs targeting lipid II include the bacterial lantibiotic-type bacteriocins, such as nisin or epidermin, which also use lipid II as docking molecule for subsequent pore formation [89,90]. In addition to vancomycin and lantibiotics, the human AMPs HNP-1 and HBD-3 target lipid II to block cell wall biosynthesis [91,92]. Finally, there are reports of resistance to lysozyme that is conferred by acetylation of MurNAc [93] or deacetylation of GlcNAc [94].

Similar to Gram-positive bacteria, Gram-negative bacteria accomplish resistance to AMPs by alteration of net charge and permeability of the cell surface. The counterpart of TA in Gram-negative bacteria is LPS, which forms the main component of the outer leaflet of the OM, covering 75% of the cell surface [95] and causing a net negative surface charge. Prevention of electrostatic binding of AMPs to the Gram-negative cell surface is achieved by amine-containing molecules (amino sugars, phosphoethanolamine (PEA) or glycine), which increase the positive charge of the anionic LPS component lipid A. *P. aeruginosa* and *S. typhimurium* attach aminoarabinose to a phosphate group in lipid A [96,97]. *Acinetobacter baumannii*, *Francisella novicida* and *Bordetella* species modify lipid A phosphate with galactosamine or glucosamine [98–101]. Furthermore, Gram-negative bacteria use PEA to decrease the anionic properties of LPS. *S. typhimurium*, *Neisseria gonorrhoeae* and *A. baumannii* attach PEA onto phosphates in lipid A [101–103]. Finally, *Vibrio cholerae* imports glycines into lipid A acyl chains to increase the positive charge and diminish AMP attraction [104]. Especially *Burkholderia* species and *N. meningitidis* constitutively express aminoarabinose- and PEA-attached lipid A, respectively; thus, inherently they have higher AMP resistance than other bacteria [105,106]. In addition to adding positively charged molecules to LPS, Gram-negative bacteria can obtain the same result by removing anionic phosphate groups from lipid A. In *F. novicida*, the LpxE and LpxF proteins have phosphatase activities, catalysing the removal of phosphate from the 1 and 4′ position of lipid A, respectively [107,108]. In contrast, LpxT is responsible for additional phosphorylation on lipid A [109,110]. Activation of LpxE/LpxF and inhibition of LpxT may contribute to AMP resistance in Gram-negative bacteria by decreasing the net negative charge [111–113]. Finally, it has recently been discovered that LPS dephosphorylation by LpxF is critical for survival of the human gut commensal *Bacteroidetes*, by protecting this bacterium from inflammatory perturbation originating from AMPs [114].

Another strategy of increasing AMP resistance in Gram-negative bacteria is to enhance the rigidity of the OM by adding extra acyl chains into lipid A [115,116]. Lipid A acylation is often mediated by the PagP enzyme, which was shown to promote resistance to various AMPs such as C18G, protegrin, polymyxin B, LL-37 and magainin II in *S. typhimurium*, *E. coli*, *Yersinia enterocolitica* and *V. cholerae* [115–117]. Furthermore, in a recent study on *A. baumannii*, which does not have PagP, homologues of LpxL and LpxM were shown to promote lipid A acylation to prevent the activities of C18G and polymyxin [118].

In addition to changing surface charge and permeability of the OM, the outermost long polysaccharide chain in LPS, called O-antigen, confers an extra AMP barrier to Gram-negative bacteria [72]. Both LPS core and the O-antigen have been proven essential for AMP resistance in *B. cenocepacia* and *Brucella abortus* using mutants that lack the respective sugar structures in LPS [119,120].

Finally, during symbiotic interaction with insects, changes in the bacterial surface structure are observed that decrease AMP resistance and increase susceptibility to host innate immune defences. Namely, *Burkholderia* species were shown to lose the LPS O-antigen during symbiotic colonization of the gut of the bean bug, *Riptortus pedestris*, resulting in increased susceptibility to purified host AMPs [121]. For a detailed review on insect–symbiont interaction, the reader is referred to the article by Masson *et al.* [122].

5. Alteration of the cytoplasmic membrane structure

After passing through all the outer barriers on the bacterial surface, AMPs finally confront the cytoplasmic membrane. Because this is the major target of AMPs, bacteria frequently have strategies to modify the membrane in a fashion that decreases AMP attraction and insertion. The most abundant phospholipids in bacterial membranes are phosphatidylglycerol (PG) and diphosphatidylglycerol (DPG, also called cardiolipin), which have anionic head groups that attract CAMPs. This attraction may be perturbed, for example, by amino-acylation of the PG head group, which masks anionic phosphates with cationic primary amines. Originally described in *S. aureus*, the bifunctional, integral membrane protein, multipeptide resistance factor (MprF) is responsible for amino-acylation of PG with lysine, which results in AMP resistance by electrostatic repulsion [123]. The C-terminal synthase domain of MprF uses PG and aminoacyl–tRNA as substrates. The synthesized aminoacyl-PG is translocated to the outer leaflet of the cytoplasmic membrane by an N-terminal flippase domain in MprF [124]. In a recent study performed in *S. aureus*, further detailed structural information on MprF, the only known bacterial phospholipid flippase, was revealed, including multi-domain interaction and oligomerization [125]. MprF proteins of different bacteria use different amino acid and phospholipid substrates, an adaptation that may explain why MprF is widely spread among bacteria except for enterobacteria [126]. While the majority of bacteria including *Staphylococcus* and *Bacillus* species only generate Lys-PG from PG and lysyl-tRNA, some other bacteria use a different combination of substrates: Lys-PG and Lys-CL in *Listeria monocytogenes* [127], Ala-PG in *P. aeruginosa* [128], Lys-PG and Ala-PG in *Clostridium perfringens* [129]. Compared with other bacteria that are devoid of MprF such as group A or B streptococci [76,130], staphylococci have an especially thick cationic surface barrier, possibly explaining why staphylococci are particularly resistant to CAMPs. Although PG lysylation has been reported mostly in Gram-positive bacteria, there are some studies that report the presence of Lys-PG in Gram-negative bacteria such as *Caulobacter crescentus* [131], *Rhizobium tropici* [132] and *P. aeruginosa*.

In addition to lipid A, the PagP protein also palmitoylates PG on the OM [133]. As PagP is involved in the homeostasis of membrane hydrophobicity, it is certainly imaginable that the protein may also repair AMP-damaged membranes, which would constitute another AMP resistance mechanism [134]. In general, higher membrane rigidity can be achieved by an increase of saturated acyl chains in the membrane, which has been reported to confer elevated resistance to pediocin and nisin in *E. faecalis* and *L. monocytogenes*, respectively [135,136]. In *S. aureus*, enhanced membrane rigidity can be achieved by increased incorporation of the carotenoid staphyloxanthin, which stabilizes acyl chains in the membrane [137]. In contrast, unsaturated fatty acyl chains increase membrane fluidity, which underlies resistance to thrombin-induced platelet microbicidal proteins (tPMP) in *S. aureus* [138]. Generally, the roles of membrane rigidity and fluidity in AMP resistance are still ambiguous and will require enhanced research efforts.

6. Efflux pumps

Even when AMPs have already attached to and inserted in the cytoplasmic membrane, bacteria can still remove them using dedicated efflux pumps, which constitute another important AMP resistance component. The resistance/nodulation/cell division (RND) family transporters, AMP efflux pumps that are present in many Gram-negative bacteria, have been studied for some time [139,140]. A typical member of this family is composed of three components: an inner membrane proton/AMP antiporter, an OM transporter and a periplasmic accessory protein that completes and stabilizes the entire efflux complex [141,142]. For example, MtrCDE of *N. gonorrhoeae* and *N. meningitides* is responsible for resistance to LL-37 and protegrin-1 [106,143]. AcrAB-TolC in *K. pneumoniae* is active on polymyxin B as well as human defensins (HNP-1, HBD-1, 2) [144]. Finally, *V. cholerae* VexAB-TolC protects from polymyxin B [145]. Importantly, some RND family efflux pumps from other bacteria have no function in AMP resistance. In those cases (e.g. AcrAB-TolC of *E. coli*, MexAB-OprM of *P. aeruginosa*), no significant differences in the susceptibilities towards cathelicidin, and various human defensins could be observed using overexpression and isogenic efflux pump gene deletion strains [146]. Finally, in another Gram-negative pathogen, *Y. enterocolitica*, RosAB, a major facilitator superfamily (MFS) efflux pump was reported to confer resistance to polymyxin B [147].

Similar to the *S. aureus* MFS family efflux protein NorA [146], most staphylococcal multidrug-resistance transporters are not active on human AMPs. However, the *S. aureus* MFS efflux pump, QacA, has been shown to confer resistance to tPMP [148]. Including in *S. aureus*, a large number of AMP-exporting efflux pumps in Gram-positive bacteria are ATP-binding cassette (ABC) transporters that are designated for the secretion of, or producer immunity towards, newly synthesized AMPs [149]. For example, NisT of *Lactococcus lactis* exports newly synthesized nisin [150] and EpiFEG of *S. epidermidis* protects from epidermin and the structurally similar gallidermin [151]. Notably, these proteins have a limited role in general AMP resistance because of their narrow substrate specificity. However, the other group of two-component ABC transporters, called BceAB type, are active on a wider range of AMPs, including lantibiotics, cyclic AMPs, glycopeptides, cathelicidin and defensins [149]. While most BceAB-type transporters accept as substrates only one or two classes of AMPs (mostly lantibiotics and bacitracin), the *S. aureus* VraFG ABC transporter confers resistance to a variety of AMPs, including nisin, bacitracin, vancomycin, indolicidin,

LL-37 and HBD-3 [149,152,153]. In addition, *S. aureus* has two more BceAB-type ABC transporters, BraDE and VraDE, but their substrates are limited to nisin and bacitracin [154–156]. BceAB-type ABC transporters have been also found in *B. subtilis*, *S. pneumoniae*, *L. monocytogenes* and many other Gram-positive bacteria [149,157–160]. Of note, this type of transporter often appears to be involved with AMP sensing (see §7). Finally, a unique *S. pneumoniae* dual efflux pump of both the MFS and ABC families, MefE/Mel, is inducible by cathelicidin, and confers resistance to LL-37 as well as macrolides [161,162].

7. Antimicrobial peptide sensing systems

Although some bacterial AMP resistance mechanisms, such as the modification of lipid II, represent constitutive changes, most are strictly regulated by bacterial sensor/regulators. This is likely to minimize a fluctuation in anionic homeostasis and expression of energy-consuming resistance mechanisms when they are not needed.

The first Gram-positive AMP sensing system was identified in *S. epidermidis* and named antimicrobial peptide sensor (Aps), also known as GraRS or GraRSX [163]. It is unusual in comprising three components: a membrane-bound AMP sensing histidine kinase (ApsS), a DNA-binding response regulator (ApsR) and a third component (ApsX) of yet unknown function, all of which are essential for AMP-dependent gene regulation. The Aps system regulates the expression of genes involved in major AMP resistance mechanisms, such as the *dlt* operon for TA alanylation, the *mprF* gene for PG lysinylation and the *vraFG* ABC transporter. The latter was recently reported to also be involved in AMP-dependent signal transduction [153]. Interestingly, a very short extracellular loop in ApsS interacts with AMPs and determines substrate specificity [152]. Aps-homologous systems are found in multiple Gram-positive pathogens including *S. pneumoniae*, *L. monocytogenes*, *Bacillus anthracis*, *Clostridium difficile* and *Staphylococcus haemolyticus* [163]. Other Gram-positive two-component systems that sense AMPs and regulate resistance mechanisms include BceSR of *B. subtilis* [157], BraSR, VraSR in *S. aureus* [154] and LiaFSR in streptococci [164,165]. Often, they cooperate with corresponding ABC transporters, such as VraFG in the case of Aps [153].

A central regulator for AMP resistance in Gram-negative bacteria is the PhoPQ two-component system [166,167]. PhoQ is a histidine kinase sensor located in the cytoplasmic membrane and PhoP is the corresponding DNA-binding response regulator. PhoPQ and a further PhoPQ-regulated two-component system, PmrAB, work together to regulate most lipid A modifications involved with AMP resistance, which include PagP-mediated palmitoylation, amine-compound addition to phosphates and alteration of the degree of phosphorylation in lipid A [97,102,107,108,113, 115,168]. PhoPQ-homologous systems for AMP resistance are found in various Gram-negative bacteria, including *S. typhimurium*, *Y. pestis* and *Shigella flexneri* [169–172]. *Sodalis glossinidius*, an endosymbiont of the tsetse fly, also has the PhoP/PhoQ system, but by loss of PhoP's sensory capacity constitutively expresses genes facilitating resistance to host AMPs during colonization [173].

8. Conclusion

Mechanisms of resistance to AMPs are widespread in bacteria. Many of those are based on changes in the physico-chemical properties of surface molecules and the cytoplasmic membrane. These changes commonly confer moderate levels of resistance and are relatively non-specific. Possibly, they are not exclusively involved with AMP resistance. For example, the primary task of many surface molecules is the formation of a biofilm matrix and that of many secreted proteases the acquisition of nutrients, and most AMP efflux pumps also accept other antimicrobial molecules as substrates. For drug development efforts in the field of AMPs, it is important that AMP resistance, which may develop due to selective pressure [174], is thus not based on dedicated resistance genes that are conferred, such as in the case of many antibiotic resistance mechanisms, by horizontal gene transfer [175]. Rather, these observations mean that for any AMP-based drug, a certain increase of resistance after exposure to the drug is to be expected ('MIC creep'), such as observed for the AMP-related antibiotic, daptomycin [126,176].

Even if many details about bacterial resistance to AMPs have been discovered, several topics await more in-depth investigation, such as membrane repair mechanisms, the role of membrane fluidity/rigidity, the involvement of host components and resistance mechanisms of the Gram-negative inner membrane.

References

1. Peschel A, Sahl HG. 2006 The co-evolution of host cationic antimicrobial peptides and microbial resistance. *Nat. Rev. Microbiol.* **4**, 529–536. (doi:10. 1038/nrmicro1441)
2. Otto M. 2010 *Staphylococcus* colonization of the skin and antimicrobial peptides. *Expert Rev. Dermatol.* **5**, 183–195. (doi:10.1586/edm.10.6)
3. Yang D *et al.* 1999 Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. *Science* **286**, 525–528. (doi:10.1126/science. 286.5439.525)
4. Brown KL, Hancock RE. 2006 Cationic host defense (antimicrobial) peptides. *Curr. Opin. Immunol.* **18**, 24–30. (doi:10.1016/j.coi.2005.11.004)
5. Ganz T. 2003 Defensins: antimicrobial peptides of innate immunity. *Nat. Rev. Immunol.* **3**, 710–720. (doi:10.1038/nri1180)
6. Durr UH, Sudheendra US, Ramamoorthy A. 2006 LL-37, the only human member of the cathelicidin family of antimicrobial peptides. *Biochim. Biophys. Acta* **1758**, 1408–1425. (doi:10.1016/j.bbamem. 2006.03.030)
7. Schittek B *et al.* 2001 Dermcidin: a novel human antibiotic peptide secreted by sweat glands. *Nat. Immunol.* **2**, 1133–1137. (doi:10.1038/ni732)
8. Song C *et al.* 2013 Crystal structure and functional mechanism of a human antimicrobial membrane channel. *Proc. Natl Acad. Sci. USA* **110**, 4586–4591. (doi:10.1073/pnas.1214739110)
9. Fjell CD, Hiss JA, Hancock RE, Schneider G. 2012 Designing antimicrobial peptides: form follows function. *Nat. Rev. Drug Discov.* **11**, 37–51. (doi:10. 1038/nrd3591)

10. Sieprawska-Lupa M et al. 2004 Degradation of human antimicrobial peptide LL-37 by *Staphylococcus aureus*-derived proteinases. *Antimicrob. Agents Chemother.* **48**, 4673–4679. (doi:10.1128/AAC.48.12.4673-4679.2004)

11. Teufel P, Gotz F. 1993 Characterization of an extracellular metalloprotease with elastase activity from *Staphylococcus epidermidis*. *J. Bacteriol.* **175**, 4218–4224.

12. Schmidtchen A, Frick IM, Andersson E, Tapper H, Bjorck L. 2002 Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37. *Mol. Microbiol.* **46**, 157–168. (doi:10.1046/j.1365-2958.2002.03146.x)

13. Baranska-Rybak W, Sonesson A, Nowicki R, Schmidtchen A. 2006 Glycosaminoglycans inhibit the antibacterial activity of LL-37 in biological fluids. *J. Antimicrob. Chemother.* **57**, 260–265. (doi:10.1093/jac/dki460)

14. Nelson DC, Garbe J, Collin M. 2011 Cysteine proteinase SpeB from *Streptococcus pyogenes* – a potent modifier of immunologically important host and bacterial proteins. *Biol. Chem.* **392**, 1077–1088. (doi:10.1515/BC.2011.208)

15. Frick IM, Nordin SL, Baumgarten M, Morgelin M, Sorensen OE, Olin AI, Egesten A. 2011 Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal *Finegoldia magna* and the pathogen *Streptococcus pyogenes*. *J. Immunol.* **187**, 4300–4309. (doi:10.4049/jimmunol.1004179)

16. Rasmussen M, Muller HP, Bjorck L. 1999 Protein GRAB of *Streptococcus pyogenes* regulates proteolysis at the bacterial surface by binding alpha2-macroglobulin. *J. Biol. Chem.* **274**, 15 336–15 344. (doi:10.1074/jbc.274.22.15336)

17. Nyberg P, Rasmussen M, Bjorck L. 2004 Alpha2-macroglobulin-proteinase complexes protect *Streptococcus pyogenes* from killing by the antimicrobial peptide LL-37. *J. Biol. Chem.* **279**, 52 820–52 823. (doi:10.1074/jbc.C400485200)

18. Schmidtchen A, Frick IM, Bjorck L. 2001 Dermatan sulphate is released by proteinases of common pathogenic bacteria and inactivates antibacterial alpha-defensin. *Mol. Microbiol.* **39**, 708–713. (doi:10.1046/j.1365-2958.2001.02251.x)

19. Haiko J, Suomalainen M, Ojala T, Lahteenmaki K, Korhonen TK. 2009 Invited review: Breaking barriers–attack on innate immune defences by omptin surface proteases of enterobacterial pathogens. *Innate Immun.* **15**, 67–80. (doi:10.1177/1753425909102559)

20. Kukkonen M, Korhonen TK. 2004 The omptin family of enterobacterial surface proteases/adhesins: from housekeeping in *Escherichia coli* to systemic spread of *Yersinia pestis*. *Int. J. Med. Microbiol.* **294**, 7–14. (doi:10.1016/j.ijmm.2004.01.003)

21. Stumpe S, Schmid R, Stephens DL, Georgiou G, Bakker EP. 1998 Identification of OmpT as the protease that hydrolyzes the antimicrobial peptide protamine before it enters growing cells of *Escherichia coli*. *J. Bacteriol.* **180**, 4002–4006.

22. Guina T, Yi EC, Wang H, Hackett M, Miller SI. 2000 A PhoP-regulated outer membrane protease of *Salmonella enterica serovar typhimurium* promotes resistance to alpha-helical antimicrobial peptides. *J. Bacteriol.* **182**, 4077–4086. (doi:10.1128/JB.182.14.4077-4086.2000)

23. Galvan EM, Lasaro MA, Schifferli DM. 2008 Capsular antigen fraction 1 and Pla modulate the susceptibility of *Yersinia pestis* to pulmonary antimicrobial peptides such as cathelicidin. *Infect. Immun.* **76**, 1456–1464. (doi:10.1128/IAI.01197-07)

24. Belas R, Manos J, Suvanasuthi R. 2004 *Proteus mirabilis* ZapA metalloprotease degrades a broad spectrum of substrates, including antimicrobial peptides. *Infect. Immun.* **72**, 5159–5167. (doi:10.1128/Iai.72.9.5159-5167.2004)

25. Kooi C, Sokol PA. 2009 *Burkholderia cenocepacia* zinc metalloproteases influence resistance to antimicrobial peptides. *Microbiology* **155**, 2818–2825. (doi:10.1099/mic.0.028969-0)

26. Groisman EA, Parra-Lopez C, Salcedo M, Lipps CJ, Heffron F. 1992 Resistance to host antimicrobial peptides is necessary for *Salmonella* virulence. *Proc. Natl Acad. Sci. USA* **89**, 11 939–11 943. (doi:10.1073/pnas.89.24.11939)

27. Parra-Lopez C, Baer MT, Groisman EA. 1993 Molecular genetic analysis of a locus required for resistance to antimicrobial peptides in *Salmonella typhimurium*. *EMBO J.* **12**, 4053–4062.

28. Mason KM, Munson Jr RS, Bakaletz LO. 2005 A mutation in the *sap* operon attenuates survival of nontypeable *Haemophilus influenzae* in a chinchilla model of otitis media. *Infect. Immun.* **73**, 599–608. (doi:10.1128/IAI.73.1.599-608.2005)

29. Mason KM, Bruggeman ME, Munson RS, Bakaletz LO. 2006 The non-typeable *Haemophilus influenzae* Sap transporter provides a mechanism of antimicrobial peptide resistance and SapD-dependent potassium acquisition. *Mol. Microbiol.* **62**, 1357–1372. (doi:10.1111/j.1365-2958.2006.05460.x)

30. Shelton CL, Raffel FK, Beatty WL, Johnson SM, Mason KM. 2011 Sap transporter mediated import and subsequent degradation of antimicrobial peptides in *Haemophilus*. *PLoS Pathog.* **7**, e1002360. (doi:10.1371/journal.ppat.1002360)

31. Mason KM, Raffel FK, Ray WC, Bakaletz LO. 2011 Heme utilization by nontypeable *Haemophilus influenzae* is essential and dependent on Sap transporter function. *J. Bacteriol.* **193**, 2527–2535. (doi:10.1128/JB.01313-10)

32. Bierbaum G, Sahl HG. 2009 Lantibiotics: mode of action, biosynthesis and bioengineering. *Curr. Pharm. Biotechnol.* **10**, 2–18. (doi:10.2174/138920109787048616)

33. Bokarewa M, Tarkowski A. 2004 Human alpha-defensins neutralize fibrinolytic activity exerted by staphylokinase. *Thromb. Haemost.* **91**, 991–999. (doi:10.1267/THRO04050991)

34. Jin T, Bokarewa M, Foster T, Mitchell J, Higgins J, Tarkowski A. 2004 *Staphylococcus aureus* resists human defensins by production of staphylokinase, a novel bacterial evasion mechanism. *J. Immunol.* **172**, 1169–1176. (doi:10.4049/jimmunol.172.2.1169)

35. Braff MH, Jones AL, Skerrett SJ, Rubens CE. 2007 *Staphylococcus aureus* exploits cathelicidin antimicrobial peptides produced during early pneumonia to promote staphylokinase-dependent fibrinolysis. *J. Infect. Dis.* **195**, 1365–1372. (doi:10.1086/513277)

36. Sun H et al. 2004 Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. *Science* **305**, 1283–1286. (doi:10.1126/science.1101245)

37. Hollands A, Gonzalez D, Leire E, Donald C, Gallo RL, Sanderson-Smith M, Dorrestein PC, Nizet V. 2012 A bacterial pathogen co-opts host plasmin to resist killing by cathelicidin antimicrobial peptides. *J. Biol. Chem.* **287**, 40 891–40 897. (doi:10.1074/jbc.M112.404582)

38. Frick IM, Akesson P, Rasmussen M, Schmidtchen A, Bjorck L. 2003 SIC, a secreted protein of *Streptococcus pyogenes* that inactivates antibacterial peptides. *J. Biol. Chem.* **278**, 16 561–16 566. (doi:10.1074/jbc.M301995200)

39. Akesson P, Sjoholm AG, Bjorck L. 1996 Protein SIC, a novel extracellular protein of *Streptococcus pyogenes* interfering with complement function. *J. Biol. Chem.* **271**, 1081–1088. (doi:10.1074/jbc.271.2.1081)

40. Lauth X, von Kockritz-Blickwede M, McNamara CW, Myskowski S, Zinkernagel AS, Beall B, Ghosh P, Gallo RL, Nizet V. 2009 M1 protein allows group A streptococcal survival in phagocyte extracellular traps through cathelicidin inhibition. *J. Innate Immun.* **1**, 202–214. (doi:10.1159/000203645)

41. Maisey HC, Quach D, Hensler ME, Liu GY, Gallo RL, Nizet V, Doran KS. 2008 A group B streptococcal pilus protein promotes phagocyte resistance and systemic virulence. *FASEB J.* **22**, 1715–1724. (doi:10.1096/fj.07-093963)

42. Costerton JW, Stewart PS, Greenberg EP. 1999 Bacterial biofilms: a common cause of persistent infections. *Science* **284**, 1318–1322. (doi:10.1126/science.284.5418.1318)

43. Otto M. 2006 Bacterial evasion of antimicrobial peptides by biofilm formation. *Curr. Top. Microbiol. Immunol.* **306**, 251–258. (doi:10.1007/3-540-29916-5_10)

44. Mah TF, O'Toole GA. 2001 Mechanisms of biofilm resistance to antimicrobial agents. *Trends Microbiol.* **9**, 34–39. (doi:10.1016/S0966-842X(00)01913-2)

45. Nickel JC, Ruseska I, Wright JB, Costerton JW. 1985 Tobramycin resistance of *Pseudomonas aeruginosa* cells growing as a biofilm on urinary catheter material. *Antimicrob. Agents Chemother.* **27**, 619–624. (doi:10.1128/AAC.27.4.619)

46. Otto M. 2012 Molecular basis of *Staphylococcus epidermidis* infections. *Semin. Immunopathol.* **34**, 201–214. (doi:10.1007/s00281-011-0296-2)

47. Wang X, Preston III JF, Romeo T. 2004 The *pgaABCD* locus of *Escherichia coli* promotes the synthesis of a polysaccharide adhesin required for biofilm formation. *J. Bacteriol.* **186**, 2724–2734. (doi:10.1128/JB.186.9.2724-2734.2004)

48. Vuong C, Voyich JM, Fischer ER, Braughton KR, Whitney AR, DeLeo FR, Otto M. 2004 Polysaccharide intercellular adhesin (PIA) protects *Staphylococcus epidermidis* against major components of the human innate immune system. *Cell Microbiol.* **6**, 269–275. (doi:10.1046/j.1462-5822.2004.00367.x)

49. Vuong C, Kocianova S, Voyich JM, Yao Y, Fischer ER, DeLeo FR, Otto M. 2004 A crucial role for exopolysaccharide modification in bacterial biofilm formation, immune evasion, and virulence. *J. Biol. Chem.* **279**, 54 881–54 886. (doi:10.1074/jbc.M411374200)

50. Heilmann C, Schweitzer O, Gerke C, Vanittanakom N, Mack D, Gotz F. 1996 Molecular basis of intercellular adhesion in the biofilm-forming *Staphylococcus epidermidis*. *Mol. Microbiol.* **20**, 1083–1091. (doi:10.1111/j.1365-2958.1996.tb02548.x)

51. Rupp ME, Ulphani JS, Fey PD, Bartscht K, Mack D. 1999 Characterization of the importance of polysaccharide intercellular adhesin/hemagglutinin of *Staphylococcus epidermidis* in the pathogenesis of biomaterial-based infection in a mouse foreign body infection model. *Infect. Immun.* **67**, 2627–2632.

52. Campos MA, Vargas MA, Regueiro V, Llompart CM, Alberti S, Bengoechea JA. 2004 Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides. *Infect. Immun.* **72**, 7107–7114. (doi:10.1128/Iai.72.12.7107-7114.2004)

53. Llobet E, Tomas JM, Bengoechea JA. 2008 Capsule polysaccharide is a bacterial decoy for antimicrobial peptides. *Microbiology* **154**, 3877–3886. (doi:10.1099/mic.0.2008/022301-0)

54. Cole JN, Pence MA, von Kockritz-Blickwede M, Hollands A, Gallo RL, Walker MJ, Nizet V. 2010 M protein and hyaluronic acid capsule are essential for in vivo selection of covRS mutations characteristic of invasive serotype M1T1 group A *Streptococcus*. *MBio* **1**, e00191. (doi:10.1128/mBio.00191-10)

55. Buchanan JT, Stannard JA, Lauth X, Ostland VE, Powell HC, Westerman ME, Nizet V. 2005 *Streptococcus iniae* phosphoglucomutase is a virulence factor and a target for vaccine development. *Infect. Immun.* **73**, 6935–6944. (doi:10.1128/IAI.73.10.6935-6944.2005)

56. Evans LR, Linker A. 1973 Production and characterization of the slime polysaccharide of *Pseudomonas aeruginosa*. *J. Bacteriol.* **116**, 915–924.

57. Hoiby N. 1974 *Pseudomonas aeruginosa* infection in cystic fibrosis. Relationship between mucoid strains of *Pseudomonas aeruginosa* and the humoral immune response. *Acta Pathol. Microbiol. Scand. B Microbiol. Immunol.* **82**, 551–558.

58. Hentzer M, Teitzel GM, Balzer GJ, Heydorn A, Molin S, Givskov M, Parsek MR. 2001 Alginate overproduction affects *Pseudomonas aeruginosa* biofilm structure and function. *J. Bacteriol.* **183**, 5395–5401. (doi:10.1128/JB.183.18.5395-5401.2001)

59. Foschiatti M, Cescutti P, Tossi A, Rizzo R. 2009 Inhibition of cathelicidin activity by bacterial exopolysaccharides. *Mol. Microbiol.* **72**, 1137–1146. (doi:10.1111/j.1365-2958.2009.06707.x)

60. Herasimenka Y, Benincasa M, Mattiuzzo M, Cescutti P, Gennaro R, Rizzo R. 2005 Interaction of antimicrobial peptides with bacterial polysaccharides from lung pathogens. *Peptides* **26**, 1127–1132. (doi:10.1016/j.peptides.2005.01.020)

61. Spinosa MR, Progida C, Tala A, Cogli L, Alifano P, Bucci C. 2007 The *Neisseria meningitidis* capsule is important for intracellular survival in human cells. *Infect. Immun.* **75**, 3594–3603. (doi:10.1128/IAI.01945-06)

62. Jones A, Georg M, Maudsdotter L, Jonsson AB. 2009 Endotoxin, capsule, and bacterial attachment contribute to *Neisseria meningitidis* resistance to the human antimicrobial peptide LL-37. *J. Bacteriol.* **191**, 3861–3868. (doi:10.1128/JB.01313-08)

63. Ogunleye A, Bhat A, Irorere VU, Hill D, Williams C, Radecka I. 2015 Poly-gamma-glutamic acid: production, properties and applications. *Microbiology* **161**, 1–17. (doi:10.1099/mic.0.081448-0)

64. Kocianova S, Vuong C, Yao Y, Voyich JM, Fischer ER, DeLeo FR, Otto M. 2005 Key role of poly-gamma-DL-glutamic acid in immune evasion and virulence of *Staphylococcus epidermidis*. *J. Clin. Invest.* **115**, 688–694. (doi:10.1172/JCI23523)

65. Candela T, Fouet A. 2006 Poly-gamma-glutamate in bacteria. *Mol. Microbiol.* **60**, 1091–1098. (doi:10.1111/j.1365-2958.2006.05179.x)

66. Otto M. 2008 Staphylococcal biofilms. *Curr. Top. Microbiol. Immunol.* **322**, 207–228. (doi:10.1007/978-3-540-75418-3_10)

67. Yao Y, Sturdevant DE, Otto M. 2005 Genomewide analysis of gene expression in *Staphylococcus epidermidis* biofilms: insights into the pathophysiology of *S. epidermidis* biofilms and the role of phenol-soluble modulins in formation of biofilms. *J. Infect. Dis.* **191**, 289–298. (doi:10.1086/426945)

68. Batoni G, Maisetta G, Brancatisano FL, Esin S, Campa M. 2011 Use of antimicrobial peptides against microbial biofilms: advantages and limits. *Curr. Med. Chem.* **18**, 256–279. (doi:10.2174/092986711794088399)

69. Strempel N, Strehmel J, Overhage J. 2015 Potential application of antimicrobial peptides in the treatment of bacterial biofilm infections. *Curr. Pharm. Des.* **21**, 67–84. (doi:10.2174/1381612820666140905124312)

70. Joo HS, Otto M. 2012 Molecular basis of in vivo biofilm formation by bacterial pathogens. *Chem. Biol.* **19**, 1503–1513. (doi:10.1016/j.chembiol.2012.10.022)

71. Di Luca M, Maccari G, Nifosi R. 2014 Treatment of microbial biofilms in the post-antibiotic era: prophylactic and therapeutic use of antimicrobial peptides and their design by bioinformatics tools. *Pathog. Dis.* **70**, 257–270. (doi:10.1111/2049-632X.12151)

72. Silhavy TJ, Kahne D, Walker S. 2010 The bacterial cell envelope. *Cold Spring Harb. Perspect. Biol.* **2**, a000414. (doi:10.1101/cshperspect.a000414)

73. Bera A, Biswas R, Herbert S, Kulauzovic E, Weidenmaier C, Peschel A, Gotz F. 2007 Influence of wall teichoic acid on lysozyme resistance in *Staphylococcus aureus*. *J. Bacteriol.* **189**, 280–283. (doi:10.1128/JB.01221-06)

74. Kojima N, Araki Y, Ito E. 1985 Structure of the linkage units between ribitol teichoic acids and peptidoglycan. *J. Bacteriol.* **161**, 299–306.

75. Peschel A, Otto M, Jack RW, Kalbacher H, Jung G, Gotz F. 1999 Inactivation of the *dlt* operon in *Staphylococcus aureus* confers sensitivity to defensins, protegrins, and other antimicrobial peptides. *J. Biol. Chem.* **274**, 8405–8410. (doi:10.1074/jbc.274.13.8405)

76. Saar-Dover R, Bitler A, Nezer R, Shmuel-Galia L, Firon A, Shimoni E, Trieu-Cuot P, Shai Y. 2012 D-Alanylation of lipoteichoic acids confers resistance to cationic peptides in Group B *Streptococcus* by increasing the cell wall density. *PLoS Pathog.* **8**, e1002891. (doi:10.1371/journal.ppat.1002891)

77. Abachin E, Poyart C, Pellegrini E, Milohanic E, Fiedler F, Berche P, Trieu-Cuot P. 2002 Formation of D-alanyl-lipoteichoic acid is required for adhesion and virulence of *Listeria monocytogenes*. *Mol. Microbiol.* **43**, 1–14. (doi:10.1046/j.1365-2958.2002.02723.x)

78. Kristian SA, Datta V, Weidenmaier C, Kansal R, Fedtke I, Peschel A, Gallo RL, Nizet V. 2005 D-Alanylation of teichoic acids promotes Group A *Streptococcus* antimicrobial peptide resistance, neutrophil survival, and epithelial cell invasion. *J. Bacteriol.* **187**, 6719–6725. (doi:10.1128/JB.187.19.6719-6725.2005)

79. Fabretti F, Theilacker C, Baldassarri L, Kaczynski Z, Kropec A, Holst O, Huebner J. 2006 Alanine esters of enterococcal lipoteichoic acid play a role in biofilm formation and resistance to antimicrobial peptides. *Infect. Immun.* **74**, 4164–4171. (doi:10.1128/IAI.00111-06)

80. Kovacs M, Halfmann A, Fedtke I, Heintz M, Peschel A, Vollmer W, Hakenbeck R, Bruckner R. 2006 A functional *dlt* operon, encoding proteins required for incorporation of D-alanine in teichoic acids in Gram-positive bacteria, confers resistance to cationic antimicrobial peptides in *Streptococcus pneumoniae*. *J. Bacteriol.* **188**, 5797–5805. (doi:10.1128/JB.00336-06)

81. Chan KG, Mayer M, Davis EM, Halperin SA, Lin TJ, Lee SF. 2007 Role of D-alanylation of *Streptococcus gordonii* lipoteichoic acid in innate and adaptive immunity. *Infect. Immun.* **75**, 3033–3042. (doi:10.1128/IAI.01549-06)

82. Abi Khattar Z et al. 2009 The *dlt* operon of *Bacillus cereus* is required for resistance to cationic antimicrobial peptides and for virulence in insects. *J. Bacteriol.* **191**, 7063–7073. (doi:10.1128/JB.00892-09)

83. Revilla-Guarinos A, Gebhard S, Alcantara C, Staron A, Mascher T, Zuniga M. 2013 Characterization of a regulatory network of peptide antibiotic detoxification modules in *Lactobacillus casei* BL23. *Appl. Environ. Microbiol.* **79**, 3160–3170. (doi:10.1128/AEM.00178-13)

84. Taneja NK, Ganguly T, Bakaletz LO, Nelson KJ, Dubey P, Poole LB, Deora R. 2013 D-Alanine modification of a protease-susceptible outer membrane component by the *Bordetella pertussis dra* locus promotes resistance to antimicrobial peptides and polymorphonuclear leukocyte-mediated killing. *J. Bacteriol.* **195**, 5102–5111. (doi:10.1128/JB.00510-13)

85. Carvalho F, Atilano ML, Pombinho R, Covas G, Gallo RL, Filipe SR, Sousa S, Cabanes D. 2015 L-Rhamnosylation of *Listeria monocytogenes* wall teichoic acids promotes resistance to antimicrobial peptides by delaying interaction with the membrane. *PLoS Pathog.* **11**, e1004919. (doi:10.1371/journal.ppat.1004919)

86. van Heijenoort J. 2007 Lipid intermediates in the biosynthesis of bacterial peptidoglycan. *Microbiol. Mol. Biol. Rev.* **71**, 620–635. (doi:10.1128/MMBR.00016-07)

87. Kahne D, Leimkuhler C, Lu W, Walsh C. 2005 Glycopeptide and lipoglycopeptide antibiotics. *Chem. Rev.* **105**, 425–448. (doi:10.1021/cr030103a)

88. Bugg TD, Wright GD, Dutka-Malen S, Arthur M, Courvalin P, Walsh CT. 1991 Molecular basis for vancomycin resistance in *Enterococcus faecium* BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. *Biochemistry* **30**, 10 408–10 415. (doi:10.1021/bi00107a007)

89. Brotz H, Josten M, Wiedemann I, Schneider U, Gotz F, Bierbaum G, Sahl HG. 1998 Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. *Mol. Microbiol.* **30**, 317–327. (doi:10.1046/j.1365-2958.1998.01065.x)

90. Breukink E, Wiedemann I, van Kraaij C, Kuipers OP, Sahl HG, de Kruijff B. 1999 Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. *Science* **286**, 2361–2364. (doi:10.1126/science.286.5448.2361)

91. de Leeuw E, Li C, Zeng P, Li C, Diepeveen-de Buin M, Lu WY, Breukink E, Lu W. 2010 Functional interaction of human neutrophil peptide-1 with the cell wall precursor lipid II. *FEBS Lett.* **584**, 1543–1548. (doi:10.1016/j.febslet.2010.03.004)

92. Sass V, Schneider T, Wilmes M, Korner C, Tossi A, Novikova N, Shamova O, Sahl HG. 2010 Human beta-defensin 3 inhibits cell wall biosynthesis in staphylococci. *Infect. Immun.* **78**, 2793–2800. (doi:10.1128/IAI.00688-09)

93. Bera A, Biswas R, Herbert S, Gotz F. 2006 The presence of peptidoglycan O-acetyltransferase in various staphylococcal species correlates with lysozyme resistance and pathogenicity. *Infect. Immun.* **74**, 4598–4604. (doi:10.1128/IAI.00301-06)

94. Vollmer W, Tomasz A. 2000 The *pgdA* gene encodes for a peptidoglycan *N*-acetylglucosamine deacetylase in *Streptococcus pneumoniae*. *J. Biol. Chem.* **275**, 20 496–20 501. (doi:10.1074/jbc.M910189199)

95. Whitfield C, Trent MS. 2014 Biosynthesis and export of bacterial lipopolysaccharides. *Annu. Rev. Biochem.* **83**, 99–128. (doi:10.1146/annurev-biochem-060713-035600)

96. Moskowitz SM, Ernst RK, Miller SI. 2004 PmrAB, a two-component regulatory system of *Pseudomonas aeruginosa* that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. *J. Bacteriol.* **186**, 575–579. (doi:10.1128/JB.186.2.575-579.2004)

97. Gunn JS, Lim KB, Krueger J, Kim K, Guo L, Hackett M, Miller SI. 1998 PmrA-PmrB-regulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance. *Mol. Microbiol.* **27**, 1171–1182. (doi:10.1046/j.1365-2958.1998.00757.x)

98. Llewellyn AC *et al.* 2012 NaxD is a deacetylase required for lipid A modification and *Francisella* pathogenesis. *Mol. Microbiol.* **86**, 611–627. (doi:10.1111/mmi.12004)

99. Kanistanon D *et al.* 2008 A *Francisella* mutant in lipid A carbohydrate modification elicits protective immunity. *PLoS Pathog.* **4**, e24. (doi:10.1371/journal.ppat.0040024)

100. Shah NR, Hancock RE, Fernandez RC. 2014 *Bordetella pertussis* lipid A glucosamine modification confers resistance to cationic antimicrobial peptides and increases resistance to outer membrane perturbation. *Antimicrob. Agents Chemother.* **58**, 4931–4934. (doi:10.1128/AAC.02590-14)

101. Pelletier MR, Casella LG, Jones JW, Adams MD, Zurawski DV, Hazlett KR, Doi Y, Ernst RK. 2013 Unique structural modifications are present in the lipopolysaccharide from colistin-resistant strains of *Acinetobacter baumannii*. *Antimicrob. Agents Chemother.* **57**, 4831–4840. (doi:10.1128/AAC.00865-13)

102. Lee H, Hsu FF, Turk J, Groisman EA. 2004 The PmrA-regulated *pmrC* gene mediates phosphoethanolamine modification of lipid A and polymyxin resistance in *Salmonella enterica*. *J. Bacteriol.* **186**, 4124–4133. (doi:10.1128/JB.186.13.4124-4133.2004)

103. Lewis LA, Shafer WM, Dutta Ray T, Ram S, Rice PA. 2013 Phosphoethanolamine residues on the lipid A moiety of *Neisseria gonorrhoeae* lipooligosaccharide modulate binding of complement inhibitors and resistance to complement killing. *Infect. Immun.* **81**, 33–42. (doi:10.1128/IAI.00751-12)

104. Hankins JV, Madsen JA, Giles DK, Brodbelt JS, Trent MS. 2012 Amino acid addition to *Vibrio cholerae* LPS establishes a link between surface remodeling in Gram-positive and Gram-negative bacteria. *Proc. Natl Acad. Sci. USA* **109**, 8722–8727. (doi:10.1073/pnas.1201313109)

105. Loutet SA, Valvano MA. 2011 Extreme antimicrobial peptide and polymyxin B resistance in the genus *Burkholderia*. *Front. Microbiol.* **2**, 159. (doi:10.3389/fmicb.2011.00159)

106. Tzeng YL, Ambrose KD, Zughaier S, Zhou X, Miller YK, Shafer WM, Stephens DS. 2005 Cationic antimicrobial peptide resistance in *Neisseria meningitidis*. *J. Bacteriol.* **187**, 5387–5396. (doi:10.1128/JB.187.15.5387-5396.2005)

107. Wang X, Karbarz MJ, McGrath SC, Cotter RJ, Raetz CR. 2004 MsbA transporter-dependent lipid A 1-dephosphorylation on the periplasmic surface of the inner membrane: topography of *Francisella novicida* LpxE expressed in *Escherichia coli*. *J. Biol. Chem.* **279**, 49 470–49 478. (doi:10.1074/jbc.M409078200)

108. Wang X, McGrath SC, Cotter RJ, Raetz CR. 2006 Expression cloning and periplasmic orientation of the *Francisella novicida* lipid A 4'-phosphatase LpxF. *J. Biol. Chem.* **281**, 9321–9330. (doi:10.1074/jbc.M600435200)

109. Jones JW, Shaffer SA, Ernst RK, Goodlett DR, Turecek F. 2008 Determination of pyrophosphorylated forms of lipid A in Gram-negative bacteria using a multivaried mass spectrometric approach. *Proc. Natl Acad. Sci. USA* **105**, 12 742–12 747. (doi:10.1073/pnas.0800445105)

110. Touze T, Tran AX, Hankins JV, Mengin-Lecreulx D, Trent MS. 2008 Periplasmic phosphorylation of lipid A is linked to the synthesis of undecaprenyl phosphate. *Mol. Microbiol.* **67**, 264–277. (doi:10.1111/j.1365-2958.2007.06044.x)

111. Karbarz MJ, Kalb SR, Cotter RJ, Raetz CR. 2003 Expression cloning and biochemical characterization of a *Rhizobium leguminosarum* lipid A 1-phosphatase. *J. Biol. Chem.* **278**, 39 269–39 279. (doi:10.1074/jbc.M305830200)

112. Trent MS. 2004 Biosynthesis, transport, and modification of lipid A. *Biochem. Cell Biol.* **82**, 71–86. (doi:10.1139/o03-070)

113. Herrera CM, Hankins JV, Trent MS. 2010 Activation of PmrA inhibits LpxT-dependent phosphorylation of lipid A promoting resistance to antimicrobial peptides. *Mol. Microbiol.* **76**, 1444–1460. (doi:10.1111/j.1365-2958.2010.07150.x)

114. Cullen TW *et al.* 2015 Gut microbiota. Antimicrobial peptide resistance mediates resilience of prominent gut commensals during inflammation. *Science* **347**, 170–175. (doi:10.1126/science.1260580)

115. Guo L, Lim KB, Poduje CM, Daniel M, Gunn JS, Hackett M, Miller SI. 1998 Lipid A acylation and bacterial resistance against vertebrate antimicrobial peptides. *Cell* **95**, 189–198. (doi:10.1016/S0092-8674(00)81750-X)

116. Bishop RE, Gibbons HS, Guina T, Trent MS, Miller SI, Raetz CR. 2000 Transfer of palmitate from phospholipids to lipid A in outer membranes of Gram-negative bacteria. *EMBO J.* **19**, 5071–5080. (doi:10.1093/emboj/19.19.5071)

117. Matson JS, Yoo HJ, Hakansson K, Dirita VJ. 2010 Polymyxin B resistance in El Tor *Vibrio cholerae* requires lipid acylation catalyzed by MsbB. *J. Bacteriol.* **192**, 2044–2052. (doi:10.1128/JB.00023-10)

118. Boll JM, Tucker AT, Klein DR, Beltran AM, Brodbelt JS, Davies BW, Trent MS. 2015 Reinforcing lipid A acylation on the cell surface of *Acinetobacter baumannii* promotes cationic antimicrobial peptide resistance and desiccation survival. *MBio* **6**, e00478. (doi:10.1128/mBio.00478-15)

119. Loutet SA, Flannagan RS, Kooi C, Sokol PA, Valvano MA. 2006 A complete lipopolysaccharide inner core oligosaccharide is required for resistance of *Burkholderia cenocepacia* to antimicrobial peptides and bacterial survival *in vivo*.

J. Bacteriol. **188**, 2073–2080. (doi:10.1128/JB.188.6.2073-2080.2006)

120. Allen CA, Adams LG, Ficht TA. 1998 Transposon-derived *Brucella abortus* rough mutants are attenuated and exhibit reduced intracellular survival. *Infect. Immun.* **66**, 1008–1016.

121. Kim JK *et al.* 2015 Insect gut symbiont susceptibility to host antimicrobial peptides caused by alteration of the bacterial cell envelope. *J. Biol. Chem.* **290**, 21 042–21 053. (doi:10.1074/jbc.M115.651158)

122. Masson F, Zaidman-Rémy A, Heddi A. 2016 Antimicrobial peptides and cell processes tracking endosymbiont dynamics. *Phil. Trans. R. Soc. B* **371**, 20150298. (doi:10.1098/rstb.2015.0298)

123. Peschel A *et al.* 2001 *Staphylococcus aureus* resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with L-lysine. *J. Exp. Med.* **193**, 1067–1076. (doi:10.1084/jem.193.9.1067)

124. Ernst CM, Staubitz P, Mishra NN, Yang SJ, Hornig G, Kalbacher H, Bayer AS, Kraus D, Peschel A. 2009 The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. *PLoS Pathog.* **5**, e1000660. (doi:10.1371/journal.ppat.1000660)

125. Ernst CM, Kuhn S, Slavetinsky CJ, Krismer B, Heilbronner S, Gekeler C, Kraus D, Wagner S, Peschel A. 2015 The lipid-modifying multiple peptide resistance factor is an oligomer consisting of distinct interacting synthase and flippase subunits. *MBio* **6**, e02340. (doi:10.1128/mBio.02340-14)

126. Ernst CM, Peschel A. 2011 Broad-spectrum antimicrobial peptide resistance by MprF-mediated aminoacylation and flipping of phospholipids. *Mol. Microbiol.* **80**, 290–299. (doi:10.1111/j.1365-2958.2011.07576.x)

127. Thedieck K, Hain T, Mohamed W, Tindall BJ, Nimtz M, Chakraborty T, Wehland J, Jansch L. 2006 The MprF protein is required for lysinylation of phospholipids in listerial membranes and confers resistance to cationic antimicrobial peptides (CAMPs) on *Listeria monocytogenes*. *Mol. Microbiol.* **62**, 1325–1339. (doi:10.1111/j.1365-2958.2006.05452.x)

128. Klein S *et al.* 2009 Adaptation of *Pseudomonas aeruginosa* to various conditions includes tRNA-dependent formation of alanyl-phosphatidylglycerol. *Mol. Microbiol.* **71**, 551–565. (doi:10.1111/j.1365-2958.2008.06562.x)

129. Johnston NC, Baker JK, Goldfine H. 2004 Phospholipids of *Clostridium perfringens*: a reexamination. *FEMS Microbiol. Lett.* **233**, 65–68. (doi:10.1016/j.femsle.2004.01.048)

130. LaRock CN, Nizet V. 2015 Cationic antimicrobial peptide resistance mechanisms of streptococcal pathogens. *Biochim. Biophys. Acta* **1848**, 3047–3054. (doi:10.1016/j.bbamem.2015.02.010)

131. Jones DE, Smith JD. 1979 Phospholipids of the differentiating bacterium *Caulobacter crescentus*. *Can. J. Biochem.* **57**, 424–428. (doi:10.1139/o79-054)

132. Sohlenkamp C, Galindo-Lagunas KA, Guan Z, Vinuesa P, Robinson S, Thomas-Oates J, Raetz CR,

Geiger O. 2007 The lipid lysyl-phosphatidylglycerol is present in membranes of *Rhizobium tropici* CIAT899 and confers increased resistance to polymyxin B under acidic growth conditions. *Mol. Plant Microbe Interact.* **20**, 1421–1430. (doi:10.1094/MPMI-20-11-1421)

133. Dalebroux ZD, Matamouros S, Whittington D, Bishop RE, Miller SI. 2014 PhoPQ regulates acidic glycerophospholipid content of the *Salmonella typhimurium* outer membrane. *Proc. Natl Acad. Sci. USA* **111**, 1963–1968. (doi:10.1073/pnas.1316901111)

134. Band VI, Weiss DS. 2015 Mechanisms of antimicrobial peptide resistance in Gram-negative bacteria. *Antibiotics* (*Basel*) **4**, 18–41. (doi:10.3390/antibiotics4010018)

135. Kumariya R, Sood SK, Rajput YS, Saini N, Garsa AK. 2015 Increased membrane surface positive charge and altered membrane fluidity leads to cationic antimicrobial peptide resistance in *Enterococcus faecalis*. *Biochim. Biophys. Acta* **1848**, 1367–1375. (doi:10.1016/j.bbamem.2015.03.007)

136. Mazzotta AS, Montville TJ. 1997 Nisin induces changes in membrane fatty acid composition of *Listeria monocytogenes* nisin-resistant strains at 10 degrees C and 30 degrees C. *J. Appl. Microbiol.* **82**, 32–38. (doi:10.1111/j.1365-2672.1997.tb03294.x)

137. Mishra NN, Liu GY, Yeaman MR, Nast CC, Proctor RA, McKinnell J, Bayer AS. 2011 Carotenoid-related alteration of cell membrane fluidity impacts *Staphylococcus aureus* susceptibility to host defense peptides. *Antimicrob. Agents Chemother.* **55**, 526–531. (doi:10.1128/AAC.00680-10)

138. Bayer AS *et al.* 2000 *In vitro* resistance of *Staphylococcus aureus* to thrombin-induced platelet microbicidal protein is associated with alterations in cytoplasmic membrane fluidity. *Infect. Immun.* **68**, 3548–3553. (doi:10.1128/IAI.68.6.3548-3553.2000)

139. Piddock LJ. 2006 Multidrug-resistance efflux pumps - not just for resistance. *Nat. Rev. Microbiol.* **4**, 629–636. (doi:10.1038/nrmicro1464)

140. Delmar JA, Su CC, Yu EW. 2014 Bacterial multidrug efflux transporters. *Annu. Rev. Biophys.* **43**, 93–117. (doi:10.1146/annurev-biophys-051013-022855)

141. Piddock LJ. 2006 Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. *Clin. Microbiol. Rev.* **19**, 382–402. (doi:10.1128/CMR.19.2.382-402.2006)

142. Ruggerone P, Murakami S, Pos KM, Vargiu AV. 2013 RND efflux pumps: structural information translated into function and inhibition mechanisms. *Curr. Top. Med. Chem.* **13**, 3079–3100. (doi:10.2174/15680266113136660220)

143. Shafer WM, Qu X, Waring AJ, Lehrer RI. 1998 Modulation of *Neisseria gonorrhoeae* susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family. *Proc. Natl Acad. Sci. USA* **95**, 1829–1833. (doi:10.1073/pnas.95.4.1829)

144. Padilla E, Llobet E, Domenech-Sanchez A, Martinez-Martinez L, Bengoechea JA, Alberti S. 2010 *Klebsiella pneumoniae* AcrAB efflux pump contributes to antimicrobial resistance and

virulence. *Antimicrob. Agents Chemother.* **54**, 177–183. (doi:10.1128/AAC.00715-09)

145. Bina XR, Provenzano D, Nguyen N, Bina JE. 2008 *Vibrio cholerae* RND family efflux systems are required for antimicrobial resistance, optimal virulence factor production, and colonization of the infant mouse small intestine. *Infect. Immun.* **76**, 3595–3605. (doi:10.1128/IAI.01620-07)

146. Rieg S, Huth A, Kalbacher H, Kern WV. 2009 Resistance against antimicrobial peptides is independent of *Escherichia coli* AcrAB, *Pseudomonas aeruginosa* MexAB and *Staphylococcus aureus* NorA efflux pumps. *Int. J. Antimicrob Agents* **33**, 174–176. (doi:10.1016/j.ijantimicag.2008.07.032)

147. Bengoechea JA, Skurnik M. 2000 Temperature-regulated efflux pump/potassium antiporter system mediates resistance to cationic antimicrobial peptides in *Yersinia*. *Mol. Microbiol.* **37**, 67–80. (doi:10.1046/j.1365-2958.2000.01956.x)

148. Kupferwasser LI, Skurray RA, Brown MH, Firth N, Yeaman MR, Bayer AS. 1999 Plasmid-mediated resistance to thrombin-induced platelet microbicidal protein in staphylococci: role of the *qacA* locus. *Antimicrob. Agents Chemother.* **43**, 2395–2399.

149. Gebhard S. 2012 ABC transporters of antimicrobial peptides in *Firmicutes* bacteria − phylogeny, function and regulation. *Mol. Microbiol.* **86**, 1295–1317. (doi:10.1111/mmi.12078)

150. Qiao M, Saris PE. 1996 Evidence for a role of NisT in transport of the lantibiotic nisin produced by *Lactococcus lactis* N8. *FEMS Microbiol. Lett.* **144**, 89–93. (doi:10.1111/j.1574-6968.1996.tb08513.x)

151. Otto M, Peschel A, Gotz F. 1998 Producer self-protection against the lantibiotic epidermin by the ABC transporter EpiFEG of *Staphylococcus epidermidis* Tu3298. *FEMS Microbiol. Lett.* **166**, 203–211.

152. Li M, Cha DJ, Lai Y, Villaruz AE, Sturdevant DE, Otto M. 2007 The antimicrobial peptide-sensing system *aps* of *Staphylococcus aureus*. *Mol. Microbiol.* **66**, 1136–1147. (doi:10.1111/j.1365-2958.2007.05986.x)

153. Falord M, Karimova G, Hiron A, Msadek T. 2012 GraXSR proteins interact with the VraFG ABC transporter to form a five-component system required for cationic antimicrobial peptide sensing and resistance in *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* **56**, 1047–1058. (doi:10.1128/AAC.05054-11)

154. Hiron A, Falord M, Valle J, Debarbouille M, Msadek T. 2011 Bacitracin and nisin resistance in *Staphylococcus aureus*: a novel pathway involving the BraS/BraR two-component system (SA2417/SA2418) and both the BraD/BraE and VraD/VraE ABC transporters. *Mol. Microbiol.* **81**, 602–622. (doi:10.1111/j.1365-2958.2011.07735.x)

155. Yoshida Y, Matsuo M, Oogai Y, Kato F, Nakamura N, Sugai M, Komatsuzawa H. 2011 Bacitracin sensing and resistance in *Staphylococcus aureus*. *FEMS Microbiol. Lett.* **320**, 33–39. (doi:10.1111/j.1574-6968.2011.02291.x)

156. Kolar SL *et al.* 2011 NsaRS is a cell-envelope-stress-sensing two-component system of *Staphylococcus*

aureus. Microbiology **157**, 2206–2219. (doi:10.1099/mic.0.049692-0)

157. Ohki R, Giyanto, Tateno K, Masuyama W, Moriya S, Kobayashi K, Ogasawara N. 2003 The BceRS two-component regulatory system induces expression of the bacitracin transporter, BceAB, in *Bacillus subtilis. Mol. Microbiol.* **49**, 1135–1144. (doi:10.1046/j.1365-2958.2003.03653.x)

158. Becker P, Hakenbeck R, Henrich B. 2009 An ABC transporter of *Streptococcus pneumoniae* involved in susceptibility to vancoresmycin and bacitracin. *Antimicrob. Agents Chemother.* **53**, 2034–2041. (doi:10.1128/AAC.01485-08)

159. Collins B, Curtis N, Cotter PD, Hill C, Ross RP. 2010 The ABC transporter AnrAB contributes to the innate resistance of *Listeria monocytogenes* to nisin, bacitracin, and various beta-lactam antibiotics. *Antimicrob. Agents Chemother.* **54**, 4416–4423. (doi:10.1128/AAC.00503-10)

160. Nawrocki KL, Crispell EK, McBride SM. 2014 Antimicrobial peptide resistance mechanisms of Gram-positive bacteria. *Antibiotics (Basel)* **3**, 461–492. (doi:10.3390/antibiotics3040461)

161. Ambrose KD, Nisbet R, Stephens DS. 2005 Macrolide efflux in *Streptococcus pneumoniae* is mediated by a dual efflux pump (*mel* and *mef*) and is erythromycin inducible. *Antimicrob. Agents Chemother.* **49**, 4203–4209. (doi:10.1128/AAC.49.10.4203-4209.2005)

162. Zahner D, Zhou X, Chancey ST, Pohl J, Shafer WM, Stephens DS. 2010 Human antimicrobial peptide LL-37 induces MefE/Mel-mediated macrolide resistance in *Streptococcus pneumoniae. Antimicrob.*

Agents Chemother. **54**, 3516–3519. (doi:10.1128/AAC.01756-09)

163. Li M, Lai Y, Villaruz AE, Cha DJ, Sturdevant DE, Otto M. 2007 Gram-positive three-component antimicrobial peptide-sensing system. *Proc. Natl Acad. Sci. USA* **104**, 9469–9474. (doi:10.1073/pnas.0702159104)

164. Eldholm V, Gutt B, Johnsborg O, Bruckner R, Maurer P, Hakenbeck R, Mascher T, Havarstein LS. 2010 The pneumococcal cell envelope stress-sensing system LiaFSR is activated by murein hydrolases and lipid II-interacting antibiotics. *J. Bacteriol.* **192**, 1761–1773. (doi:10.1128/JB.01489-09)

165. Suntharalingam P, Senadheera MD, Mair RW, Levesque CM, Cvitkovitch DG. 2009 The LiaFSR system regulates the cell envelope stress response in *Streptococcus mutans. J. Bacteriol.* **191**, 2973–2984. (doi:10.1128/JB.01563-08)

166. Miller SI, Kukral AM, Mekalanos JJ. 1989 A two-component regulatory system (phoP phoQ) controls *Salmonella typhimurium* virulence. *Proc. Natl Acad. Sci. USA* **86**, 5054–5058. (doi:10.1073/pnas.86.13.5054)

167. Groisman EA, Chiao E, Lipps CJ, Heffron F. 1989 *Salmonella typhimurium* phoP virulence gene is a transcriptional regulator. *Proc. Natl Acad. Sci. USA* **86**, 7077–7081. (doi:10.1073/pnas.86.18.7077)

168. Gunn JS, Miller SI. 1996 PhoP-PhoQ activates transcription of *pmrAB*, encoding a two-component regulatory system involved in *Salmonella typhimurium* antimicrobial peptide resistance. *J. Bacteriol.* **178**, 6857–6864.

169. Bader MW, Sanowar S, Daley ME, Schneider AR, Cho U, Xu W, Klevit RE, Le Moual H, Miller SI. 2005 Recognition of antimicrobial peptides by a bacterial

sensor kinase. *Cell* **122**, 461–472. (doi:10.1016/j.cell.2005.05.030)

170. Oyston PC, Dorrell N, Williams K, Li SR, Green M, Titball RW, Wren BW. 2000 The response regulator PhoP is important for survival under conditions of macrophage-induced stress and virulence in *Yersinia pestis. Infect. Immun.* **68**, 3419–3425. (doi:10.1128/IAI.68.6.3419-3425.2000)

171. Rebeil R, Ernst RK, Gowen BB, Miller SI, Hinnebusch BJ. 2004 Variation in lipid A structure in the pathogenic yersiniae. *Mol. Microbiol.* **52**, 1363–1373. (doi:10.1111/j.1365-2958.2004.04059.x)

172. Moss JE, Fisher PE, Vick B, Groisman EA, Zychlinsky A. 2000 The regulatory protein PhoP controls susceptibility to the host inflammatory response in *Shigella flexneri. Cell Microbiol.* **2**, 443–452. (doi:10.1046/j.1462-5822.2000.00065.x)

173. Pontes MH, Smith KL, De Vooght L, Van Den Abbeele J, Dale C. 2011 Attenuation of the sensing capabilities of PhoQ in transition to obligate insect–bacterial association. *PLoS Genet.* **7**, e1002349. (doi:10.1371/journal.pgen.1002349)

174. Perron GG, Zasloff M, Bell G. 2006 Experimental evolution of resistance to an antimicrobial peptide. *Proc. R. Soc. B* **273**, 251–256. (doi:10.1098/rspb.2005.3301)

175. Juhas M. 2015 Horizontal gene transfer in human pathogens. *Crit. Rev. Microbiol.* **41**, 101–108. (doi:10.3109/1040841X.2013.804031)

176. Baltz RH. 2009 Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. *Curr. Opin. Chem. Biol.* **13**, 144–151. (doi:10.1016/j.cbpa.2009.02.031)

11

rstb.royalsocietypublishing.org   *Phil. Trans. R. Soc. B* **371**: 20150292